| Pharmaceutical Information |
| Drug Name |
Secnidazole |
| Drug ID |
BADD_D02512 |
| Description |
Secnidazole is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In September 2017, FDA granted approval to secnidazole under the market name Solosec as a single-dose oral treatment for bacterial vaginosis, which is a common vaginal infection in women aged 15 to 44 years. The antimicrobial therapy is only intended to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria [FDA Label]. |
| Indications and Usage |
Secnidazole is indicated for the treatment of trichomoniasis in adults and bacterial vaginosis in adult women.[L39524] |
| Marketing Status |
approved |
| ATC Code |
P01AB07 |
| DrugBank ID |
DB12834
|
| KEGG ID |
D07353
|
| MeSH ID |
C016724
|
| PubChem ID |
71815
|
| TTD Drug ID |
D0V5IW
|
| NDC Product Code |
11014-0236; 27437-051; 14799-2008; 51552-1632; 71052-367; 49574-526; 49964-0047 |
| UNII |
R3459K699K
|
| Synonyms |
secnidazole | 1-(2'-hydroxypropyl)-2-methyl-5- nitroimidazole | 14,539 RP | Secnol | Sabima | Secnidal | Solosec | Minovag |
|
| Chemical Information |
| Molecular Formula |
C7H11N3O3 |
| CAS Registry Number |
3366-95-8 |
| SMILES |
CC1=NC=C(N1CC(C)O)[N+](=O)[O-] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
